Anticancer Research 2011-07-01

A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.

Hiroshi Tsujioka, Tatsuya Fukami, Fusanori Yotsumoto, Taeko Ueda, Shoko Hikita, Yoko Takahashi, Haruhiko Kondo, Masahide Kuroki, Shingo Miyamoto

文献索引：Anticancer Res. 31(7) , 2461-5, (2011)

全文：HTML全文

摘要

Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a promising target for cancer therapy. We have already started a phase I study of CRM197, a specific HB-EGF inhibitor, for advanced ovarian cancer. In this study, we evaluated possible clinical adaptations of CRM197 in combination with conventional chemotherapeutic agents.CRM197, bevacizumab, and paclitaxel were intraperitoneally administered either alone or in combination with mice xenografted with ES2 human ovarian cancer cells. The tumor volumes and microvessel densities (MVD) were determined.Enhanced antitumor effects were observed when paclitaxel was used in combination with bevacizumab or CRM197. The antitumor effect of paclitaxel/CRM197 was significantly higher than that of paclitaxel/bevacizumab. The tumor MVD of mice treated with paclitaxel/CRM197 was significantly lower than that of mice treated with paclitaxel/bevacizumab.CRM197 in combination with paclitaxel significantly blocked tumor formation and angiogenesis. These results suggest that paclitaxel is a suitable candidate for CRM197 combination therapy.